Study of a new drug (CKD-703) for advanced solid tumors and lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have an advanced solid tumor or non-small cell lung cancer that has a protein called c-Met on its surface (confirmed by a lab test).
- Your cancer has worsened after at least one standard treatment, or you could not tolerate the side effects.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have at least 12 weeks of life expectancy, and your tumor can be measured on scans.
- You have not received certain types of prior treatments that target c-Met or contain MMAE, and you have not had lung radiation within the last 6 months or certain eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial is testing an investigational drug called SYS6077 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if this drug is a safe option for patients who have run out of other choices.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.